KMT2A and leukemia: Menin inhibitors are also emerging as promising therapeutic agents against KMT2A-rearranged leukemias, with an overall response rate of 55% and a favorable adverse event profile from the Augment-101 trial; however, this should be viewed with caution given the low number of pediatric patients and that infants were not included in this trial [19].